LB Pharmaceuticals names CCO Kaya Pai Panandiker; inducement grant

LB Pharmaceuticals (LBRX) appointed Kaya Pai Panandiker as Chief Commercial Officer, effective November 10, 2025, and announced the move via a press release.

Accepted by SEC EDGAR 11/12/2025 - 08:17 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

LB Pharmaceuticals (LBRX) appointed Kaya Pai Panandiker as Chief Commercial Officer, effective November 10, 2025, and announced the move via a press release. The company also plans to grant her an equity award as an inducement to join, made outside of—but subject to—the 2025 Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). A copy of the press release is filed as Exhibit 99.1.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did LB Pharmaceuticals (LBRX) announce?

The company appointed Kaya Pai Panandiker as its Chief Commercial Officer and issued a press release (Exhibit 99.1).

When is the appointment of LBRX’s new CCO effective?

The appointment is effective November 10, 2025.

Will the new CCO receive an equity grant at LBRX?

Yes. The company intends to grant an inducement equity award outside of the plan, subject to the 2025 Equity Incentive Plan, under Nasdaq Rule 5635(c)(4).

What is Kaya Pai Panandiker’s background?

She most recently served as Chief Commercial Officer at Neumora Therapeutics, and previously held senior roles at Cerevel Therapeutics and H. Lundbeck A/S.

What exhibit was filed with this announcement?

Exhibit 99.1 contains the press release dated November 12, 2025.

What is LB Pharmaceuticals’ trading symbol and exchange?

The common stock trades under LBRX on The Nasdaq Stock Market LLC.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

false 0001691082 0001691082 2025-11-12 2025-11-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 12, 2025

LB Pharmaceuticals Inc

(Exact name of registrant as specified in its charter)

Delaware		001-42831		81-1854347
(state or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

One Pennsylvania Plaza, Suite 1025 New York, NY		10119
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (212) 605-0300

Not applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		LBRX		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On November 12, 2025, LB Pharmaceuticals Inc (the “Company”) announced that Kaya Pai Panandiker has been appointed to serve as the Company’s Chief Commercial Officer, effective as of November 10, 2025, and issued a press release.

Ms. Pai Panandiker, age 49, is joining the Company after most recently serving as the Chief Commercial Officer of Neumora Therapeutics, Inc. Previously, Ms. Pai Panandiker served as Head of Commercial at Cerevel Therapeutics Holdings, Inc. and General Manager, Neuroscience at H. Lundbeck A/S. Ms. Pai Panandiker received a B.A. from the University of Wisconsin-Madison and earned her Master’s degree in Public Policy from the University of Chicago.

As an inducement material to Ms. Pai Panandiker entering into employment with the Company, the Company intends to grant her an equity award outside of, but subject to the terms and conditions of, the Company’s 2025 Equity Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).

A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press release dated November 12, 2025.
104		Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LB Pharmaceuticals Inc
By:		/s/ Heather Turner
		Heather Turner Chief Executive Officer

Dated: November 12, 2025